PYC Therapeutics Ltd
ASX:PYC

Watchlist Manager
PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd
ASX:PYC
Watchlist
Price: 1.305 AUD -0.76% Market Closed
Market Cap: 761.2m AUD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

PYC Price Targets Summary
PYC Therapeutics Ltd

Wall Street analysts forecast PYC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PYC is 3.481 AUD with a low forecast of 2.323 AUD and a high forecast of 5.013 AUD.

PYC Lowest Forecast
Wall Street Target
2.323 AUD
78% Upside
PYC Average Forecast
Wall Street Target
3.481 AUD
167% Upside
PYC Highest Forecast
Wall Street Target
5.013 AUD
284% Upside
Lowest
Price Target
2.323 AUD
78% Upside
Average
Price Target
3.481 AUD
167% Upside
Highest
Price Target
5.013 AUD
284% Upside
PYC Therapeutics Ltd Competitors:
Price Targets
M
MAB
Mabion SA
6% Upside
ARGX
argenx SE
24% Upside
688177
Bio-Thera Solutions Ltd
9% Upside
VNDA
Vanda Pharmaceuticals Inc
183% Upside
M
MAB
Mabion SA
6% Upside
ARGX
argenx SE
24% Upside
688177
Bio-Thera Solutions Ltd
9% Upside
VNDA
Vanda Pharmaceuticals Inc
183% Upside
ONCO
Oncopeptides AB
4% Upside
NIOX
Niox Group PLC
21% Upside
AMRN
Amarin Corporation PLC
1% Upside
Y
002675
Yantai Dongcheng Biochemicals Co Ltd
12% Downside

Revenue
Forecast

Revenue Estimate
PYC Therapeutics Ltd

The compound annual growth rate of PYC Therapeutics Ltd's revenue for the next 4 years is 15%.

N/A
Past Growth
15%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
PYC Therapeutics Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
PYC Therapeutics Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
PYC intrinsic value, competitors valuation, and company profile.
DCF Valuation
PYC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PYC stock valuation using valuation multiples.
Wall Street Estimates
PYC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PYC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PYC's stock price target?
Price Target
3.481 AUD

According to Wall Street analysts, the average 1-year price target for PYC is 3.481 AUD with a low forecast of 2.323 AUD and a high forecast of 5.013 AUD.

What is PYC Therapeutics Ltd's Revenue forecast?
Projected CAGR
15%

The compound annual growth rate of PYC Therapeutics Ltd's revenue for the next 4 years is 15%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 276,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.